Every 10-Q that Enhabit, Inc. (EHAB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EHAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EHAB filings page.
Enhabit, Inc. reported solid results for the quarter ended March 31, 2026 while progressing toward a planned merger that would take the company private. Net service revenue grew to $264.8 million, up 1.9% year over year, with home health up 0.6% and hospice up 6.2%.
Net income attributable to Enhabit rose to $19.2 million, or $0.36 diluted earnings per share, compared with $17.8 million, or $0.35, a year earlier, helped by lower general and administrative costs and a litigation-related settlement gain. Adjusted EBITDA was $24.4 million versus $26.6 million.
The company refinanced its capital structure with a new $315.0 million term loan A and $160.0 million revolving credit facility maturing in 2031, leaving total debt at $428.6 million and cash and cash equivalents at $50.0 million. Enhabit also highlighted an Agreement and Plan of Merger with an affiliate of Kinderhook Industries, under which it is expected to become a wholly owned private company in the second quarter of 2026, subject to customary closing conditions.
Enhabit (EHAB) reported a return to profitability in Q3 2025. Net service revenue was $263.6M, up 3.9% year over year. Operating income reached $16.8M versus a loss in the prior year, and net income attributable to Enhabit was $11.1M, or $0.22 per diluted share, compared with a loss of $110.2M a year ago, which included a goodwill impairment.
Hospice drove the quarter with revenue of $63.1M, up 20.0%, while Home Health was $200.5M, down 0.2%. Adjusted EBITDA was $27.0M versus $24.5M. For the first nine months, revenue was $789.6M (up 1.7%) and net income was $34.1M, helped by a $19.3M gain on sale of an investment. Interest expense fell with lower borrowings and rates.
Cash rose to $56.9M, and total debt was $463.8M, including $333.5M on the term loan and $125.0M drawn on the revolver. The company closed or consolidated 13 branches year‑to‑date and remained in compliance with credit facility covenants. CMS finalized a 2.6% hospice payment increase effective October 1, 2025, and proposed a 6.4% home health decrease for 2026.